We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.
- Authors
Geffen, D B; Abu-Ghanem, S; Sion-Vardy, N; Braunstein, R; Tokar, M; Ariad, S; Delgado, B; Bayme, M; Koretz, M
- Abstract
The 21-gene recurrence score (RS) assay has been validated in retrospective studies as prognostic of distant disease recurrence and predictive of the benefit of adjuvant chemotherapy in estrogen-receptor-positive breast cancer (BC). There is limited published data on the impact of the assay on clinical practice, particularly in the context of a single practice with a unified treatment policy.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Vol 22, Issue 11, p2381
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdq769